The anxiolytic effect of cinnabar involves changes of serotonin levels

European Journal of Pharmacology

Volumn 565, Issue 1-3, 2007, Pages 132-137

  Wang, Qi ^a   Yang, Xiaoda ^a   Zhang, Baoxu ^a   Yang, Xiuwei ^a   Wang, Kui ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

(Mouse); Anxiolytic; Cinnabar; Serotonin

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BRAIN ENZYME; BRAIN MONOAMINE; MERCURY SULFIDE; MONOAMINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; MALE; MAZE TEST; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SEROTONIN METABOLISM; SEROTONINERGIC SYSTEM; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; BRAIN CHEMISTRY; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MAZE LEARNING; MERCURY COMPOUNDS; MICE; MICE, INBRED C57BL; SEROTONIN;

EID: 34249039575     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.03.018     Document Type: Article

References (37)

1. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72 (1976) 248-254
2. Briley M., Chopin P., and Moret C. Effects of serotonin lesions on anxious behaviour measured in the elevated-plus-maze test in the rat. Psychopharmacology 101 (1990) 187-189
3. Chakrabarti S.K., Loua K.M., Bai C.J., Durham H., and Panisset J.C. Modulation of monoamine oxidase activity in different brain regions and platelets following exposure of rats to methylmercury. Neurotoxicol. Teratol. 20 (1998) 161-168
4. Charney D.S., and Deutch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit. Rev. Neurobiol. 10 (1996) 419-446
5. Chopin P., and Briley M. Animal models of anxiety: the effect of compounds that modify serotonergic function. Trends Pharmacol. Sci. 8 (1987) 383-388
6. Chuu J.J., Hsu C.J., and Lin-Shiau S.Y. Abnormal auditory brainstem responses for mice treated with mercurial compounds: involvement of excessive nitric oxide. Toxicology 162 (2001) 11-22
7. Chuu J.J., Young Y.H., Liu S.H., and Lin-Shiau S.Y. Neurotoxicity of mercury sulfide in the vestibular ocular reflex system of guinea pigs. Naunyn-Schmiedeberg's Arch. Pharmacol. 364 (2001) 249-258
8. Cruz A.P.M., Frei F., and Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49 (1994) 171-176
9. Dawson G.R., and Tricklebank M.D. Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol. Sci. 16 (1995) 33-36
10. Ernst E., and Coon J.T. Heavy metals in traditional Chinese medicines: a systematic review. Clin. Pharmacol. Ther. 70 (2001) 497-504
11. Espinoza E.O., Mann M.J., and Bleasdell B. Arsenic and mercury in traditional Chinese herbal balls. New Engl. J. Med. 333 (1995) 803-804
12. File S.E. Recent developments in anxiety, stress, and depression. Pharmacol. Biochem. Behav. 54 (1996) 3-12
13. Handley S.L. 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol. Ther. 66 (1995) 103-148
14. Hardy A.D., Sutherland H.H., Vaishnav R., and Worthing M.A. A report on the composition of mercurials used in traditional medicines in Oman. J. Ethnopharmacol. 49 (1995) 17-22
15. Iverson S.D. 5-HT and anxiety. Neuropharmacology 23 (1984) 1553-1560
16. Kahawara H., Yoshida M., Yokoo H., Nishi M., and Tanaka M. Psychological stress increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis. Neurosci. Lett. 162 (1993) 81-84
17. Kang Y.E., and Oransky S.H. Chinese patent medicine as a potential source of mercury poisoning. Vet. Hum. Toxicol. 34 (1992) 235-238
18. Kent J.M., Mathew S.J., and Gorman J.M. Molecular targets in the treatment of anxiety. Biol. Psychiatry 52 (2002) 1008-1030
19. Knobelman D.A., Kung H.F., and Lucki I. Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT1A and 5-HT1B receptors. J. Pharmacol. Exp. Ther. 292 (2000) 1111-1117
20. Krajl M. A rapid microfluorometric determination of monoamine oxidase. Biochem. Pharmacol. 14 (1965) 1683-1685
21. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92 (1987) 180-185
22. Murphy D.L. Substrates-selective monoamine oxidase-inhibitor, tissues, species and functional differences. Biochem. Pharmacol. 27 (1978) 1889-1893
23. Murphy D.L., Wichems C., Li Q., and Heils A. Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission. Trends Pharmacol. Sci. 20 (1999) 246-252
24. Nagatsu T., Yamamoto T., and Harada M. Purification and properties of human brain mitochondrial monoamine oxidase. Enzymologia 39 (1970) 15-25
25. Nitta A., Furukawa Y., Hayashi K., Hiramatsu M., Kameyama T., Hasegawa T., and Nabeshima T. Denervation of dopaminergic neurons with 6-hydroxydopamine increases nerve growth factor content in rat brain. Neurosci. Lett. 144 (1992) 152-156
26. Rodgers R.J., and Cole J.C. The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper S.J., and Hendrie C.A. (Eds). Ethology and Psychopharmacology (1994), John Wiley and Sons Ltd., New York 9-44
27. Rodgers R.J., Johnson N.J.T., Champion A.J., and Mills S. Modulation of plus-maze behavior in mice by the preferential D3 receptor agonist, 7-OH-DPAT. Pharmacol. Biochem. Behav. 54 (1996) 41-50
28. Saura J., Richards J.G., and Mahy N. Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol. Aging 15 (1994) 399-408
29. Senkowski D., Linden M., Zubragel D., Bar T., and Gallinat J. Evidence for disturbed cortical signal processing and altered serotonergic neurotransmission in generalized anxiety disorder. Biol. Psychiatry 53 (2003) 304-314
30. Sperk G. Simultaneous determination of serotonin, 5-hydroxyindole-acetic acid, 3,4-dihydroxyphenylacetic acid and homovanillic acid by high performance liquid chromatography with electrochemical detection. J. Neurochem. 38 (1982) 840-843
31. Sullivan G.M., Coplan J.D., Kent J.M., and Gorman J.M. The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biol. Psychiatry 46 (1999) 1205-1218
32. Tanaka M., Yoshida M., Emoto H., and Ishii H. Noradrenaline system in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. Eur. J. Pharmacol. 405 (2000) 397-406
33. Tipton K.F., O'Carroll A.M., and McCrodden J.M. The catalytic behavior of monoamine oxidase. J. Neural Transm. 23 (1987) 25-35 (Suppl.)
34. Traber J., and Glaser T. 5-HT1A receptor-related anxiolytics. Trends Pharmacol. Sci. 8 (1987) 432-437
35. Westlund K.N., Denney R.M., Rose R.M., and Abell C.W. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25 (1988) 439-456
36. Weyler W., Hsu Y.P., and Breakfield X.O. Biochemistry and genetics of monoamine oxidase. Pharmacol. Ther. 47 (1990) 391-417
37. Young Y.H., Chuu J.J., Liu S.H., and Lin-Shiau S.Y. Neurotoxic mechanism of cinnabar and mercuric sulfide on the vestibulo-ocular reflex system of guinea pigs. Toxicol. Sci. 67 (2002) 256-263